文献速递乳腺技术与安全PETCT

ER+/HER2-转移性乳腺癌接受CDK4/6抑制剂联合内分泌治疗前¹⁸F-FDG PET/CT参数的预后意义

Prognostic Significance of Pretreatment ¹⁸F-FDG PET/CT Parameters in Patients With ER+/HER2- Metastatic Breast Cancer Treated With CDK4/6 Inhibitors Plus Endocrine Therapy.
PubMed 文献 · Korean J Radiol · 2026-01-01

该回顾性单中心队列研究纳入2018至2023年间374例ER+/HER2-转移性乳腺癌患者,在启动CDK4/6抑制剂联合内分泌治疗前行¹⁸F-FDG PET/CT,测量SUVmax、全身MTV和TLG。多因素Cox分析显示,所有连续PET参数均与PFS和OS独立相关,基于中位值二分类的参数结果相似,提示其可能用于风险分层。

要点

  • 治疗前SUVmax、MTV、TLG升高与ER+/HER2-转移性乳腺癌CDK4/6抑制剂联合内分泌治疗后PFS和OS独立相关。
  • 二分类分析中SUVmax≥7.6、MTV≥21.2 cm³、TLG≥78.9与PFS和OS不良相关。
  • PET参数可能有助于该人群治疗前的风险分层。

核心结论

  • 治疗前¹⁸F-FDG PET/CT参数是ER+/HER2-转移性乳腺癌接受CDK4/6抑制剂联合内分泌治疗患者的独立预后标志物,支持其用于风险分层的潜在价值。

研究设计与样本

  • 回顾性单中心队列研究,纳入2018至2023年间374例ER+/HER2-转移性乳腺癌患者,在启动CDK4/6抑制剂联合内分泌治疗前行¹⁸F-FDG PET/CT,测量SUVmax、全身MTV和TLG,以PFS为主要结局、OS为次要结局,采用多因素Cox模型分析。

诊断标准与关键数值

  • 连续变量多因素Cox分析:SUVmax与PFS的校正HR 1.05(95%CI 1.02-1.08),与OS的校正HR 1.08(95%CI 1.04-1.11),均P<0.001。
  • 连续变量多因素Cox分析:对数转换MTV与PFS的校正HR 1.16(95%CI 1.08-1.25),与OS的校正HR 1.24(95%CI 1.12-1.38),均P<0.001。
  • 连续变量多因素Cox分析:对数转换TLG与PFS的校正HR 1.14(95%CI 1.07-1.23),与OS的校正HR 1.22(95%CI 1.11-1.34),均P<0.001。
  • 二分类变量多因素Cox分析:SUVmax≥7.6与PFS的校正HR 1.41(95%CI 1.08-1.85),与OS的校正HR 1.43(95%CI 1.01-2.04),P≤0.046。
  • 二分类变量多因素Cox分析:MTV≥21.2 cm³与PFS的校正HR 1.41(95%CI 1.08-1.86),与OS的校正HR 1.84(95%CI 1.28-2.66);TLG≥78.9与PFS的校正HR 1.51(95%CI 1.14-1.99),与OS的校正HR 1.73(95%CI 1.20-2.50),P≤0.046。

临床应用与阅片要点

  • 治疗前¹⁸F-FDG PET/CT测量的SUVmax、全身MTV和TLG可为ER+/HER2-转移性乳腺癌接受CDK4/6抑制剂联合内分泌治疗的患者提供预后风险分层信息。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy (ET) constitute the standard systemic treatment for estrogen receptor-positive, human epidermal growth factor 2-negative (ER+/HER2-) metastatic breast cancer (MBC). However, treatment responses remain heterogeneous, highlighting the need for reliable prognostic markers. This study aimed to evaluate the prognostic significance of ¹⁸F-fluorodeoxyglucose (FDG) PET/CT findings in this setting.

MATERIALS AND METHODS: This retrospective single-center cohort study included patients with ER+/HER2- MBC who underwent ¹⁸F-FDG PET/CT before initiating CDK4/6 inhibitors plus ET between 2018 and 2023. Maximum standardized uptake value (SUVmax), whole-body metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were measured. Progression-free survival (PFS) and overall survival (OS) were evaluated as the primary and secondary outcomes, respectively, using multivariable Cox models. PET parameters (SUVmax, MTV, and TLG) were analyzed as both continuous and dichotomized variables based on median values, adjusting for relevant clinical covariates.

RESULTS: Among the 374 patients, 82 (21.9%) presented with de novo metastatic disease, and 357 (95.5%) received CDK4/6 inhibitors as first-line therapy. In multivariable Cox analysis, all continuous PET parameters were independently associated with PFS (adjusted hazard ratio for SUVmax 1.05 [95% confidence interval 1.02-1.08]; log-transformed MTV 1.16 [1.08-1.25]; and log-transformed TLG 1.14 [1.07-1.23]) and OS (SUVmax 1.08 [1.04-1.11]; log-transformed MTV 1.24 [1.12-1.38]; and log-transformed TLG 1.22 [1.11-1.34]) with all P < 0.001. Results based on dichotomized PET parameters were similar to those obtained with continuous values: PFS (adjusted hazard ratio for SUVmax ≥ 7.6, 1.41 [1.08-1.85]; MTV ≥ 21.2 cm³, 1.41 [1.08-1.86]; and TLG ≥ 78.9, 1.51 [1.14-1.99]) with P ≤ 0.013 and OS (1.43 [1.01-2.04]; 1.84 [1.28-2.66]; and 1.73 [1.20-2.50], respectively) with P ≤ 0.046.

CONCLUSION: Pretreatment ¹⁸F-FDG PET/CT parameters are independent prognostic markers in patients with ER+/HER2- MBC receiving CDK4/6 inhibitors with ET, supporting their potential utility in risk stratification.

来源:Korean J Radiol,查看原文。版权归原作者所有。

引用

  1. Suh M, Ryu J, Song H, et al. Prognostic Significance of Pretreatment ¹⁸F-FDG PET/CT Parameters in Patients With ER+/HER2- Metastatic Breast Cancer Treated With CDK4/6 Inhibitors Plus Endocrine Therapy. Korean J Radiol. 2026. PMID: 41914486. doi:10.3348/kjr.2025.1393

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。